Iovance Biotherapeutics is trading 4.44% up at $8.42, with biotech-sector momentum the strongest apparent driver as the sector advances 2.06%.
- No fresh company-specific announcement was identified on August 25, 2026.
- Broader markets remain higher, while investors show improving risk appetite.
- Record second-quarter revenue and positive Amtagvi demand remain supportive background factors, but were reported earlier and do not directly explain today’s move.